The Tumor Microenvironment in Gastrointestinal Adenocarcinomas Revealed a Prognostic and Immunotherapeutic Biomarker

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2022 Dec 31

PMID 36585927

Authors

Yong Zhang

Lu Li

Feifei Chu

Lei Zhang

Li Zhang

Huili Wu

Kunkun Li

Affiliations

Soon will be listed here.

Abstract

Accumulated evidence has elucidated that the tumor microenvironment (TME) is great of clinical significance in predicting survival outcomes and therapeutic efficacy. Nonetheless, few studies have investigated the prognostic and immunotherapeutic signature correlated with TME phenotypes in gastrointestinal adenocarcinomas (GIAC). Here, by estimating the TME pattern of immune infiltration and expression in over 1,000 GIAC patients, we revealed three TME subgroups and identified six key differential genes. To predict the TME phenotypes, TMEscore was established and validated to be an independent prognostic factor, where the high TMEscore was characterized by immune activation and response to immunotherapy and accompanied with favorable prognosis in GIAC. Furthermore, TMEscore was confirmed to predict prognosis and immunotherapeutic response in six datasets. In summary, depicting TME landscape of GIAC patients may be beneficial for interpreting survival and immunotherapeutic response, and provide new strategies for clinical treatment of GIAC.

Citing Articles

Analyzing the Functional Roles and Immunological Features of Chemokines in COAD.

Xu H, Song Y Int J Mol Sci. 2024; 25(10).

PMID: 38791448 PMC: 11121388. DOI: 10.3390/ijms25105410.

References

Hofree M, Shen J, Carter H, Gross A, Ideker T . Network-based stratification of tumor mutations. Nat Methods. 2013; 10(11):1108-15. PMC: 3866081. DOI: 10.1038/nmeth.2651. View

Feng C, Li T, Xiao J, Wang J, Meng X, Niu H . Tumor Microenvironment Profiling Identifies Prognostic Signatures and Suggests Immunotherapeutic Benefits in Neuroblastoma. Front Cell Dev Biol. 2022; 10:814836. PMC: 9047956. DOI: 10.3389/fcell.2022.814836. View

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

Song P, Li W, Guo L, Ying J, Gao S, He J . Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing. Front Immunol. 2022; 13:850745. PMC: 9231585. DOI: 10.3389/fimmu.2022.850745. View

Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou Y . mA regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020; 19(1):53. PMC: 7066851. DOI: 10.1186/s12943-020-01170-0. View

Zhang C, Li D, Yu R, Li C, Song Y, Chen X . Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature. Front Immunol. 2021; 12:651033. PMC: 8155484. DOI: 10.3389/fimmu.2021.651033. View

Liu Y, Sethi N, Hinoue T, Schneider B, Cherniack A, Sanchez-Vega F . Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell. 2018; 33(4):721-735.e8. PMC: 5966039. DOI: 10.1016/j.ccell.2018.03.010. View

Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View

Zeng D, Zhou R, Yu Y, Luo Y, Zhang J, Sun H . Gene expression profiles for a prognostic immunoscore in gastric cancer. Br J Surg. 2018; 105(10):1338-1348. PMC: 6099214. DOI: 10.1002/bjs.10871. View

10.

Ijsselsteijn M, Sanz-Pamplona R, Hermitte F, de Miranda N . Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. Mol Aspects Med. 2019; 69:123-129. DOI: 10.1016/j.mam.2019.05.003. View

11.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

12.

Zhang X, Shi M, Chen T, Zhang B . Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Mol Ther Nucleic Acids. 2020; 22:298-309. PMC: 7522342. DOI: 10.1016/j.omtn.2020.08.030. View

13.

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

14.

Zhu X, Tian X, Ji L, Zhang X, Cao Y, Shen C . A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. NPJ Precis Oncol. 2021; 5(1):7. PMC: 7881244. DOI: 10.1038/s41698-021-00142-x. View

15.

Guo W, Tan F, Huai Q, Wang Z, Shao F, Zhang G . Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma. Front Immunol. 2021; 12:669750. PMC: 8149800. DOI: 10.3389/fimmu.2021.669750. View

16.

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

17.

Jiang H, Ning G, Wang Y, Lv W . Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response. Dis Markers. 2021; 2021:5576683. PMC: 8213471. DOI: 10.1155/2021/5576683. View

18.

Bijlsma M, Sadanandam A, Tan P, Vermeulen L . Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2017; 14(6):333-342. DOI: 10.1038/nrgastro.2017.33. View

19.

Van Allen E, Miao D, Schilling B, Shukla S, Blank C, Zimmer L . Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207-211. PMC: 5054517. DOI: 10.1126/science.aad0095. View

20.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View